<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086614</url>
  </required_header>
  <id_info>
    <org_study_id>TARCRC</org_study_id>
    <nct_id>NCT05086614</nct_id>
  </id_info>
  <brief_title>Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer</brief_title>
  <official_title>The Efficacy and Safety of Thymosin-alpha 1 Used for Adjuvant Treatment After Radical Resection of High-risk Stage II and Stage III Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For high-risk stage II and stage III colorectal cancer, even after radical resection and&#xD;
      postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and&#xD;
      metastasis. Thymosin-alpha 1 is believed to improve immunity and may help promote tumor&#xD;
      immunity to reduce the incidence of recurrence and metastasis. This study hopes to verify the&#xD;
      effecacy and safety of thymosin-alpha 1 for adjuvant treatment of high-risk stage II and&#xD;
      stage III colorectal cancer after radical resection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with pathological high-risk stage II and stage III colorectal cancer after radical&#xD;
      resection were randomly allocated to receive thymosin-alpha 1 twice a week for 6 months&#xD;
      (experimental group) or not (control group) in a 1:1 ratio. At the same time, all patients&#xD;
      will receive chemo/radiotherapy according to the Chinese Standards for Diagnosis and&#xD;
      Treatment of Colorectal Cancer. The primary endpoint is 3-year DFS rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection were randomly allocated to receive thymosin-alpha 1 or not in a 1:1 ratio.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>There is no masking for participants or investigators. The outcomes assessors will be blind for the allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease-free survival rate</measure>
    <time_frame>3 years</time_frame>
    <description>percentage of patients who have no recurrence or metastases or death at 3 years after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival rate</measure>
    <time_frame>3 years</time_frame>
    <description>percentage of patients who are alive at 3 years after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of adverse events related to thymosin-alpha 1</measure>
    <time_frame>6 months</time_frame>
    <description>percentage of patients with adverse events related to thymosin-alpha 1, including fever, allergies, skin rash, liver and kidney damage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Stage II Colorectal Cancer</condition>
  <condition>Stage III Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Thymosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observe</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymosin Alpha1</intervention_name>
    <description>Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection.</description>
    <arm_group_label>Thymosin</arm_group_label>
    <other_name>Thymalfasin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Colorectal cancer receiving radical resection&#xD;
&#xD;
          -  Pathologically diagnosed with high-risk stage II or stage III&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of 0-2&#xD;
&#xD;
          -  Adequate hepatic, renal, and hematologic function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Had previously taken any immune-promoting drugs&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Xu, Dr.</last_name>
    <phone>+86-021-64041990</phone>
    <email>xujmin@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qingyang Feng, Dr.</last_name>
    <phone>+86-021-64041990</phone>
    <email>fqy198921@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianmin Xu, Dr.</last_name>
      <phone>+86-021-64041990</phone>
      <email>xujmin@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Qingyang Feng, Dr.</last_name>
      <phone>+86-021-64041990</phone>
      <email>fqy198921@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>adjuvant treatment</keyword>
  <keyword>thymosin-alpha 1</keyword>
  <keyword>disease-free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

